Third-generation EGFR-TKIs have a higher permeation ratio and specific inhibition than first- or second-generation EGFR-TKIs, inhibiting both EGFR classic mutations (EGFR 19del and EGFR L8585R), and acquired T790M-induced resistance thus would be a promising treatment strategy for NSCLC with BM (Cross et al. 2014). Here, EGFR is linked to non-small cell lung carcinoma.